ArticleInfectious agents and cancer2025
Clinical significance of HPV DNA and EGFR mutations in Egyptian NSCLC.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. While molecular profiling particularly EGFR mutation analysis has transformed therapeutic approaches, the role of viral oncogenesis, such as human papillomavirus (HPV) infection and Epstein-Barr virus (EBV), in NSCLC is less well understood. In this study, we investigated the clinical relevance of HPV/EBV infection and EGFR mutations in NSCLC.
methodsThis retrospective study analyzed tumor tissues from 93 patients with NSCLC, as well as lung tissues from 10 normal adjacent samples. HPV-DNA detection and genotyping were performed using PCR-based methods, alongside EBV-DNA analysis. EGFR mutations were assessed via exon-specific PCR amplification. Associations between HPV/EGFR status and clinicopathological parameters were evaluated, and Kaplan–Meier survival analysis was used to assess overall survival (OS) according to molecular profiles.
resultsHPV-DNA was detected in 31.2% of NSCLC tumors, while EBV-DNA was identified in 2.15%, with no positivity in normal adjacent tissues. HPV 16 was the most prevalent genotype, especially among adenocarcinoma (AC) cases. EGFR mutations were found in 20.4% of patients, predominantly in AC, with exon 19 deletions and L858R mutations being the most common. While HPV status showed no significant correlation with most clinical features, a strong inverse association was observed with surgical operability (p < 0.001). Survival analyses revealed that HPV-positive patients had shorter OS compared to HPV-negative counterparts. Patients with EGFR mutations exhibited longer OS, particularly in the HPV-negative subgroup, while the HPV-positive/EGFR-wild type group had the poorest outcomes.
conclusionThis study demonstrates distinct prevalence patterns and prognostic implications of HPV infection and EGFR mutations in NSCLC. EGFR-mutant status correlated with improved survival, while HPV positivity was associated with inoperable disease and poorer outcomes. Further validation in larger cohorts is needed before clinical application. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.